PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-1.33%
Negative revenue growth while AVGO stands at 3.32%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-11.24%
Negative gross profit growth while AVGO is at 2.36%. Joel Greenblatt would examine cost competitiveness or demand decline.
-53.58%
Negative EBIT growth while AVGO is at 9.66%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-55.16%
Negative operating income growth while AVGO is at 9.66%. Joel Greenblatt would press for urgent turnaround measures.
-50.42%
Negative net income growth while AVGO stands at 6.94%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-50.00%
Negative EPS growth while AVGO is at 6.78%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-49.02%
Negative diluted EPS growth while AVGO is at 8.77%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
-0.70%
Both firms reduce share counts. Martin Whitman would compare buyback intensity relative to free cash flow generation.
-0.35%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
31.32%
Dividend growth 1.25-1.5x AVGO's 23.23%. Bruce Berkowitz would see if management’s capital return strategy is more aggressive yet sustainable.
-14.67%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-13.44%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
169.55%
10Y revenue/share CAGR above 1.5x AVGO's 21.74%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
27.62%
5Y revenue/share CAGR 1.25-1.5x AVGO's 21.74%. Bruce Berkowitz would verify if cost efficiency or pricing power supports this advantage.
54.82%
3Y revenue/share CAGR above 1.5x AVGO's 21.74%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
75.33%
10Y OCF/share CAGR above 1.5x AVGO's 49.41%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
48.49%
5Y OCF/share CAGR is similar to AVGO's 49.41%. Walter Schloss might see parallel cost profiles or expansions producing comparable cash flow.
-2.06%
Negative 3Y OCF/share CAGR while AVGO stands at 49.41%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
461.83%
Net income/share CAGR at 50-75% of AVGO's 647.30%. Martin Whitman might question if the firm’s product or cost base lags behind.
-42.35%
Negative 5Y net income/share CAGR while AVGO is 647.30%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
214.05%
Below 50% of AVGO's 647.30%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
29.85%
Below 50% of AVGO's 124.64%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
24.58%
Below 50% of AVGO's 124.64%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
32.42%
Below 50% of AVGO's 124.64%. Michael Burry suspects a serious short-term disadvantage in building book value.
655.09%
Dividend/share CAGR of 655.09% while AVGO is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
330.01%
Dividend/share CAGR of 330.01% while AVGO is zero. Bruce Berkowitz sees a minor advantage in stepping up distributions, even modestly.
54.35%
3Y dividend/share CAGR of 54.35% while AVGO is zero. Bruce Berkowitz sees a minor positive difference that could attract dividend-focused investors.
-13.40%
Firm’s AR is declining while AVGO shows 15.09%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
-9.01%
Both reduce inventory yoy. Martin Whitman suspects a broader move to lean operations or industry slowdown in demand.
-1.96%
Negative asset growth while AVGO invests at 7.61%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
0.03%
Under 50% of AVGO's 7.71%. Michael Burry raises concerns about the firm’s ability to build intrinsic value relative to its rival.
-3.60%
We’re deleveraging while AVGO stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
20.00%
We increase R&D while AVGO cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
14.43%
We expand SG&A while AVGO cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.